Planexta Inc. (www.planexta.com) is a biotech innovations company based in California, which invented the world’s first ECG sensor for one hand (US patent pending 62/329,260 from 04/29/2016) and is dedicated to mitigating up to 80% of cardiovascular risks with different approaches of biofeedback, early diagnostic and remote care, which were metro-logically proved and peer-reviewed by specialists from Oxford University.
SenceBand™ is the first product that is engineered for the consumer market to track both emotional and physiological states, using the heart rate variability approach with medical grade accuracy. This device has already received two awards from the Consumer Electronic Show 2017 (Las Vegas, USA) in Wearable Technologies, as well as Fitness, Sport and Biotech category nominations. There was a positive feedback from media around the world during the crowdfunding campaign (including IEEE Spectrum, Cool Hunting, Digital Trends, Übergizmo, Endgadget, etc.). Successful campaign generated more than 1.000 pre-ordered units. The commercial launch will start in December 2017.
The manufacturing facilities are being prepared in Shenzhen, China. According to the preliminary inquiries from distributors, Planexta plans to sell the first 20,000 units of SenceBand™ by the end of 2018. The further development of SenceBand™ and its variations includes many more innovations.
Markets - According to IHS Technology Report, the market of home healthcare devices and services is estimated at $6 billion with an average annual growth of 25.8% during 2016-2018. A Mordor Intelligence report estimates the global market of wearable medical devices in 2015 as $3.3 billion and projects its average annual growth at 17.7% up to $7.8 billion in 2020. According to Centers for Medicare & Medicaid Services, the total amount of compensations for ECG interpretations (under Medicare Part B alone) in the United States was $162,5 million in 2015.
Market entry strategy - The company has an agile business development strategy, which includes its own distribution network, as well as special purpose vehicles with big industrial corporations.
IPR strategy - Planexta plans to protect five proprietary technologies through the International Patent System and generate data exclusivity with clinical trials of medical software and and Class II medical devices.
Pipeline - The corporate pipeline represents an enhancement of proprietary ECG sensor and its combinations, including an ensemble with multilevel PPG sensors for cuff-less blood pressure monitoring with medical grade accuracy.
Further improvement of cloud solutions is critical in terms of building a sustainable environment for risk mitigation.
The key management team behind Planexta Inc. will also take initial management oversight for Precise Cardiology Limited.
Eugene Nayshtetik, CEO and co-founder, has a 12-year managerial experience in life sciences. Worked for Pfizer, Merck, Genzyme and Novartis. Founded the Platform 20k project, which became a resource base for Planexta’s products. Earned three master’s degrees (from three universities) in international business, marketing management, and sociology & social technologies. Received dozens of certificates in medical field, including Medical Neuroscience from Duke University (USA) and Heart Rate Variability from NASM (USA). Eugene has a prominent volunteer experience in healthcare and earned different awards, including the Order of Merit (Ukraine).
Oleg Shkot and Stanislav Telyatnikov, co-founders. The two have a total of 24 years of successful entrepreneurial experience. Founded MGID (Native Advertising Marketplace) with annual turnover of $30 million (in 2015). Began their business careers with launching the redtram.com project. Oleg Shkot has a master's degrees in technology of instrument engineering and finances & credit. Stanislav Telyatnikov has a master's degree in radio engineering and a 27-year experience in software development.